Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MACOM Technology Solutions Holdings, Inc.MTSI · Entity 3267 | Director | March 04, 2022 | March 08, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MACOM Technology Solutions Holdings, Inc.
Report date March 04, 2022 · Filed March 08, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,806 |
Reported balance
After 2022-03-04 transaction · row 1
1 source rowRow 1 · 2022-03-04 · Grant · Acquired 2,768 · Balance 37,806 F1: Represents restricted stock awards granted to the Reporting Person under the Issuer's 2021 Omnibus Incentive Plan. Each restricted stock award represents the contingent right to receive one share of Common Stock. The restricted stock awards vest in full on March 4, 2023, provided that the Reporting Person remains in continuous service with the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock awards granted to the Reporting Person under the Issuer's 2021 Omnibus Incentive Plan. Each restricted stock award represents the contingent right to receive one share of Common Stock. The restricted stock awards vest in full on March 4, 2023, provided that the Reporting Person remains in continuous service with the Issuer through the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARRAY BIOPHARMA INC
Report date July 30, 2019 · Filed July 30, 2019
Section 16 reporting ended · disclosed 2019-07-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-07-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-07-30 · Disposition to issuer · Disposed 24,297 · Balance 5,000 F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. Row 2 · 2019-07-30 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes. F3: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.47 · Expires 2027-10-26 | Direct | 0 |
Reported balance
After 2019-07-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-07-30 · Disposition to issuer · Disposed 25,000 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F4: The option provided for vesting in four equal annual installments beginning on October 26, 2018. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.55 · Expires 2028-10-25 | Direct | 0 |
Reported balance
After 2019-07-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-07-30 · Disposition to issuer · Disposed 25,000 · Balance 0 F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option. F6: The option provided for vesting in four equal annual installments beginning on October 25, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 14, 2019, Array BioPharma Inc. (the "Company") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Pfizer Inc. ("Pfizer") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer ("Purchaser"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.
F2: On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes.
F3: Represents shares of Company common stock underlying each restricted stock unit (a "Company RSU") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU.
F4: The option provided for vesting in four equal annual installments beginning on October 26, 2018.
F5: Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an "In the Money Option"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option.
F6: The option provided for vesting in four equal annual installments beginning on October 25, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 21, 2018 Filed Feb 23, 2018 16:35 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 8,000 | $3.37 | $26,960.00 |
DisclosureSEC source: 0001562180-18-001195 · primarydocument.xml · nonDerivative · entry 2 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2018 Filed Feb 23, 2018 16:35 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 13,500 | $2.46 | $33,210.00 |
DisclosureSEC source: 0001562180-18-001195 · primarydocument.xml · nonDerivative · entry 1 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2018 Filed Jan 17, 2018 17:00 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001562180-18-000334 · primarydocument.xml · derivative · entry 5 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2019-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options vested in three equal annual installments commencing November 1, 2009 and ending November 1, 2011. Read SEC document |
| January 17, 2018 Filed Jan 17, 2018 17:00 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0001562180-18-000334 · primarydocument.xml · derivative · entry 4 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 6,500 shares Expires 2021-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2018 Filed Jan 17, 2018 17:00 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | SaleCommon Stock | 21,500 | $12.94 | $278,210.00 |
DisclosureSEC source: 0001562180-18-000334 · primarydocument.xml · nonDerivative · entry 3 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,297 F1 · kind: These trades were made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 17, 2018 Filed Jan 17, 2018 17:00 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 6,500 | $2.46 | $15,990.00 |
DisclosureSEC source: 0001562180-18-000334 · primarydocument.xml · nonDerivative · entry 2 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2018 Filed Jan 17, 2018 17:00 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 15,000 | $1.74 | $26,100.00 |
DisclosureSEC source: 0001562180-18-000334 · primarydocument.xml · nonDerivative · entry 1 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2017 Filed Nov 13, 2017 16:39 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Disposition to issuerCommon Stock | 1,035 | $10.90 | $11,281.50 |
DisclosureSEC source: 0001562180-17-003550 · primarydocument.xml · nonDerivative · entry 1 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,297 Read SEC document |
| October 27, 2017 Filed Oct 27, 2017 16:36 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003348 · primarydocument.xml · derivative · entry 4 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.expiration_date: RSUs awarded to the reporting person on October 27, 2016 for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The units vested and were settled in stock on October 27, 2017. Read SEC document |
| October 27, 2017 Filed Oct 27, 2017 16:36 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 5,000 | $10.47 | $52,350.00 |
DisclosureSEC source: 0001562180-17-003348 · primarydocument.xml · nonDerivative · entry 1 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares issued upon settlement of Restricted Stock Units ("RSUs") granted by the Issuer on October 27, 2016 as a result of the vesting of all such RSUs. Read SEC document |
| October 26, 2017 Filed Oct 27, 2017 16:36 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantRestricted Stock Units · Derivative | 5,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-003348 · primarydocument.xml · derivative · entry 3 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed F2 · derivative.expiration_date: RSUs awarded to the reporting person for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The units vest and will be settled in stock on October 26, 2018, subject to continued service on Array's board of directors. Read SEC document |
| October 26, 2017 Filed Oct 27, 2017 16:36 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $10.47 | $0.00 |
DisclosureSEC source: 0001562180-17-003348 · primarydocument.xml · derivative · entry 2 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-10-26 Read SEC document |
| September 29, 2017 Filed Sep 29, 2017 18:23 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionStock Option · Derivative | 45,000 | $0.00 Strike: $10.58 | $0.00 |
DisclosureSEC source: 0001562180-17-003065 · primarydocument.xml · derivative · entry 3 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2017-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form 4 is reporting the exercise by the reporting person of an option scheduled to expire on November 1, 2017 and the sale of a portion of the option shares to satisfy payment of the option exercise price. F3 · derivative.exercise_date: The option vested in 3 equal annual installments beginning on November 1, 2008. Read SEC document |
| September 29, 2017 Filed Sep 29, 2017 18:23 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | SaleCommon Stock | 39,928 | $12.36 | $493,510.08 |
DisclosureSEC source: 0001562180-17-003065 · primarydocument.xml · nonDerivative · entry 2 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,332 F2 · price: The price reported for these shares is the weighted average sale price. Details of actual prices for shares sold are available from the Issuer upon request. Read SEC document |
| September 29, 2017 Filed Sep 29, 2017 18:23 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 45,000 | $10.58 | $476,100.00 |
DisclosureSEC source: 0001562180-17-003065 · primarydocument.xml · nonDerivative · entry 1 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This Form 4 is reporting the exercise by the reporting person of an option scheduled to expire on November 1, 2017 and the sale of a portion of the option shares to satisfy payment of the option exercise price. Read SEC document |
| May 23, 2017 Filed May 25, 2017 21:56 UTC | MACOM Technology Solutions Holdings, Inc. MTSI · Entity 3267 | SaleCommon Stock | 2,000 | $60.01 | $120,020.00 |
DisclosureSEC source: 0000904454-17-000396 · edgar.xml · nonDerivative · entry 1 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,789 Read SEC document |
| April 11, 2017 Filed Apr 13, 2017 20:16 UTC | MACOM Technology Solutions Holdings, Inc. MTSI · Entity 3267 | SaleCommon Stock | 962 | $50.85 | $48,917.70 |
DisclosureSEC source: 0000904454-17-000309 · edgar.xml · nonDerivative · entry 1 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,789 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 20:34 UTC | MACOM Technology Solutions Holdings, Inc. MTSI · Entity 3267 | SaleCommon Stock | 1,000 | $46.05 | $46,050.00 |
DisclosureSEC source: 0000904454-17-000255 · edgar.xml · nonDerivative · entry 1 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,751 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| March 03, 2017 Filed Mar 7, 2017 21:16 UTC | MACOM Technology Solutions Holdings, Inc. MTSI · Entity 3267 | GrantCommon Stock | 2,835 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-17-000217 · edgar.xml · nonDerivative · entry 1 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,751 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Issuer's 2012 Omnibus Incentive Plan, as amended and restated. Each restricted stock unit represents the contingent right to receive one share of Common Stock. The restricted stock units vest on February 15, 2018, provided that the Reporting Person remains in continuous service with the Issuer through the vesting date. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 23:00 UTC | MACOM Technology Solutions Holdings, Inc. MTSI · Entity 3267 | SaleCommon Stock | 1,000 | $45.47 | $45,470.00 |
DisclosureSEC source: 0000904454-17-000201 · edgar.xml · nonDerivative · entry 1 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,916 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:55 UTC | MACOM Technology Solutions Holdings, Inc. MTSI · Entity 3267 | SaleCommon Stock | 1,000 | $46.83 | $46,830.00 |
DisclosureSEC source: 0000904454-17-000057 · edgar.xml · nonDerivative · entry 1 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,916 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| December 13, 2016 Filed Dec 15, 2016 22:32 UTC | MACOM Technology Solutions Holdings, Inc. MTSI · Entity 3267 | SaleCommon Stock | 1,000 | $49.13 | $49,130.00 |
DisclosureSEC source: 0000904454-16-001611 · edgar.xml · nonDerivative · entry 1 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,916 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 21:24 UTC | MACOM Technology Solutions Holdings, Inc. MTSI · Entity 3267 | SaleCommon Stock | 1,000 | $40.69 | $40,690.00 |
DisclosureSEC source: 0000904454-16-001578 · edgar.xml · nonDerivative · entry 1 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,916 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| October 29, 2016 Filed Oct 31, 2016 19:46 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-16-003303 · primarydocument.xml · derivative · entry 4 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.expiration_date: RSUs awarded to the reporting person on October 29, 2015 for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The units vested and were settled in stock on October 29, 2016. Read SEC document |
| October 29, 2016 Filed Oct 31, 2016 19:46 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | Exercise / conversionCommon Stock | 5,000 | $5.83 | $29,150.00 |
DisclosureSEC source: 0001562180-16-003303 · primarydocument.xml · nonDerivative · entry 1 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares issued upon settlement of Restricted Stock Units ("RSUs") granted by the Issuer on October 29, 2015 as a results of the vesting of all such RSUs. Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 19:46 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.95 | $0.00 |
DisclosureSEC source: 0001562180-16-003303 · primarydocument.xml · derivative · entry 3 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2026-10-27 Read SEC document |
| October 27, 2016 Filed Oct 31, 2016 19:46 UTC | ARRAY BIOPHARMA INC ARRY · Entity 155788 | GrantRestricted Stock Units · Derivative | 5,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-16-003303 · primarydocument.xml · derivative · entry 2 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed F2 · derivative.expiration_date: RSUs awarded to the reporting person for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The units vest and will be settled in stock on October 27, 2017, subject to continued service on Array's board of directors. Read SEC document |
| October 11, 2016 Filed Oct 13, 2016 21:18 UTC | MACOM Technology Solutions Holdings, Inc. MTSI · Entity 3267 | SaleCommon Stock | 1,000 | $42.17 | $42,170.00 |
DisclosureSEC source: 0000904454-16-001496 · edgar.xml · nonDerivative · entry 1 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,916 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
| September 13, 2016 Filed Sep 15, 2016 21:23 UTC | MACOM Technology Solutions Holdings, Inc. MTSI · Entity 3267 | SaleCommon Stock | 1,000 | $41.06 | $41,060.00 |
DisclosureSEC source: 0000904454-16-001443 · edgar.xml · nonDerivative · entry 1 VAN LUNSEN GIL J · CIK 0001205014 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,916 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.